Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Corneliu Luca et al.|The Lancet Neurology|2023Cited by 128